No Data
Investors Three-year Losses Continue as Guizhou Xinbang Pharmaceutical (SZSE:002390) Dips a Further 6.3% This Week, Earnings Continue to Decline
Guizhou Xinbang Pharmaceutical (002390.SZ): Currently, the processing capacity for Traditional Chinese Medicine decoction pieces is 6,000 tons per year, with sufficient capacity.
On February 14, Gelonghui reported that Guizhou Xinbang Pharmaceutical (002390.SZ) stated on the investor interaction platform that the company currently has a processing capacity of 6,000 tons/year for Traditional Chinese Medicine pieces, which is sufficient to meet current and short-term market demand. In the future, the company will increase the processing capacity of Traditional Chinese Medicine pieces through optimizing and adjusting the existing production workshops or expanding, in order to provide adequate support for the market.
Unpleasant Surprises Could Be In Store For Guizhou Xinbang Pharmaceutical Co., Ltd.'s (SZSE:002390) Shares
Xinbang Pharmaceuticals: 2024 Annual Results Forecast
Guizhou Xinbang Pharmaceutical (002390.SZ): The PET-CT system used by the Affiliated Tumor Hospital of Guizhou Medical University is a product of GE from the USA.
According to Gelonghui on December 31, Guizhou Xinbang Pharmaceutical (002390.SZ) stated on the investor interaction platform that the PET-CT used by its subsidiary, Guizhou Medical University Affiliated Cancer Hospital Co., Ltd., is a product of GE Company from the USA.
Guizhou Xinbang Pharmaceutical Co., Ltd.'s (SZSE:002390) Stock Is Going Strong: Have Financials A Role To Play?
Earnings Growth of 1.1% Over 3 Years Hasn't Been Enough to Translate Into Positive Returns for Guizhou Xinbang Pharmaceutical (SZSE:002390) Shareholders